Table 1 Patient cohort description
From: Testing chemotherapy efficacy in HER2 negative breast cancer using patient-derived spheroids
Characteristics | All HER negative patients | |
|---|---|---|
N | % | |
All Patients | 120 | – |
Tissue | ||
Biopsy | 77 | 61.8 |
Surgical | 43 | 38.2 |
Disease | ||
Primary | 109 | 91.1 |
Recurrent | 11 | 8.9 |
Age [years] | ||
<50 | 39 | 24.0 |
≥50 | 81 | 76.0 |
cT stage | ||
T1/T2 | 70 | 74.7 |
T3/4 | 24 | 25.3 |
Not documented | 26 | – |
cN status | ||
N+ | 49 | 48.0 |
N− | 53 | 52.0 |
Not documented | 18 | – |
cM | ||
M0 | 100 | 87.8 |
M1 | 15 | 12.2 |
Not documented | 5 | – |
Histology | ||
Invasive ductal/other | 101 | 84.2 |
Invasive lobular | 17 | 15.8 |
Not documented | 2 | – |
Grading | ||
G1/2 | 56 | 49.8 |
G3 | 57 | 50.2 |
Not documented | 7 | – |
Hormone receptor status | ||
Positive | 79 | 66.8 |
Negative | 41 | 33.2 |
ER | ||
Positive | 78 | 66.4 |
Negative | 41 | 33.6 |
Not documented | 1 | – |
PR | ||
Positive | 69 | 59.0 |
Negative | 50 | 41.0 |
Not documented | 1 | – |
Ki67 | ||
Mean (% positive stained cells) | Â | 39.22 |